Kawashima Jun, Altaf Abdullah, Endo Yutaka, Woldesenbet Selamawit, Tsilimigras Diamantis I, Rashid Zayed, Guglielmi Alfredo, Marques Hugo P, Maithel Shishir K, Groot Koerkamp Bas, Pulitano Carlo, Aucejo Federico, Endo Itaru, Pawlik Timothy M
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
HPB (Oxford). 2025 Feb;27(2):250-259. doi: 10.1016/j.hpb.2024.11.007. Epub 2024 Nov 27.
We sought to characterize the benefit of lymphadenectomy among patients undergoing curative-intent surgery for perihilar cholangiocarcinoma (pCCA) utilizing the therapeutic index.
Data on patients who underwent curative-intent resection for pCCA were obtained from 8 high-volume international hepatobiliary centers. Multivariable Cox regression analysis was used to assess clinicopathological factors associated with overall survival (OS). The therapeutic index was determined to assess the therapeutic benefit of lymphadenectomy.
Among 341 patients, median number of lymph nodes (LNs) evaluated was 7 (IQR: 4-11). A total of 127 (37.2 %) patients underwent lymphadenectomy of station 12 only, while 146 (42.8 %) patients had LNs from stations 12 plus 8 ± 13 harvested. On multivariable analysis, lymphadenectomy of stations 12 plus 8 ± 13 was associated with improved OS (referent, station 12 only: HR 0.51, 95%CI 0.32-0.80). The therapeutic index was highest among patients who underwent LN evaluation of stations 12 plus 8 ± 13 (33.1) and had ≥6 LNs harvested (26.3).
At the time of surgery of pCCA, lymphadenectomy should include station 12, as well as stations 8 and 13, with the goal to evaluate ≥6 LNs to ensure optimal staging and maximize the therapeutic benefit for patients.
我们试图利用治疗指数来描述在接受根治性手术的肝门部胆管癌(pCCA)患者中进行淋巴结清扫术的益处。
从8个大型国际肝胆中心获取接受pCCA根治性切除术患者的数据。采用多变量Cox回归分析评估与总生存期(OS)相关的临床病理因素。确定治疗指数以评估淋巴结清扫术的治疗益处。
在341例患者中,评估的淋巴结(LN)中位数为7个(四分位间距:4 - 11个)。共有127例(37.2%)患者仅接受了第12组淋巴结清扫,而146例(42.8%)患者清扫了第12组加上第8组和/或第13组的淋巴结。多变量分析显示,清扫第12组加上第8组和/或第13组淋巴结与OS改善相关(参照组,仅第12组:风险比0.51,95%置信区间0.32 - 0.80)。在接受第12组加上第8组和/或第13组淋巴结评估的患者中治疗指数最高(33.1),且清扫淋巴结≥6个的患者中治疗指数也较高(26.3)。
在pCCA手术时,淋巴结清扫应包括第12组,以及第8组和第13组,目标是评估≥6个淋巴结,以确保最佳分期并使患者的治疗益处最大化。